It’s only fair to share… NILOTINIB ニロチニブ; Molecular FormulaC28H22F3N7O Average mass529.516 Da 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluormethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzolcarboxamid 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(3-pyridinyl)-2-pyrimidinyl]amino}benzamide 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide 641571-10-0 [RN] 8654 Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- Nilotinib (AMN107, trade name Tasigna[2]), in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia.[3] Structurally related to imatinib,[4] it was developed based on the structure of the Abl-imatinib complex to …
LENALIDOMIDE, レナリドミド, леналидомид , ليناليدوميد , 来那度胺 ,
It’s only fair to share… LENALIDOMIDE Molecular FormulaC13H13N3O3 Average mass259.261 Da レナリドミド; леналидомид , ليناليدوميد , 来那度胺 , 191732-72-6 [RN] 1-Oxo-4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)- 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-piperidinedione 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidin-2,6-dion 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione 3-(7-amino-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione 8505 E3 Ligase ligand IMiD3 CAS Registry Number: 191732-72-6 CAS Name: 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione Additional Names: 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline Manufacturers’ Codes: CC-5013 Trademarks: Revimid (Celgene); Revlimid (Celgene) Molecular Formula: C13H13N3O3 Molecular Weight: 259.26 Percent Composition: C 60.22%, H 5.05%, N 16.21%, O 18.51% Literature …
Benvitimod, Tapinarof, тапинароф , تابيناروف , 他匹那罗 ,
It’s only fair to share… Benvitimod, Tapinarof 3,5-dihydroxy-4-isopropyl-trans-stilbene Launched – 2019 CHINA, Psoriasis, Tianji Pharma тапинароф [Russian] [INN]WBI-1001 تابيناروف [Arabic] [INN] 他匹那罗 [Chinese] [INN] (E)-2-(1-Methylethyl)-5-(2-phenylethenyl)-1,3-benzenediol 1,3-Benzenediol, 2-(1-methylethyl)-5-(2-phenylethenyl)-, (E)- 1,3-Benzenediol, 2-(1-methylethyl)-5-[(E)-2-phenylethenyl]- 10253 2-Isopropyl-5-[(E)-2-phenylvinyl]-1,3-benzenediol 3,5-Dihydroxy-4-isopropyl-trans-stilbene 5-[(E)-2-phenylethenyl]-2-(propan-2-yl)benzene-1,3-diol 79338-84-4 [RN] 84HW7D0V04 Research Code：WB-1001; WBI-1001 Trade Name：MOA：NSAID Indication：Atopic dermatitis; PsoriasisStatus： Phase III (Active) Company：GlaxoSmithKline (Originator), Welichem Biotech (Originator), 天济药业 (Originator) 2894512 DMVT-505 GSK-2894512 RVT-505 WB-1001 WBI-1001 84HW7D0V04 (UNII code) In May 2019, the drug …
CANERTINIB
It’s only fair to share… CANERTINIB Canertinib CAS Registry Number: 267243-28-7 CAS Name: N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide Additional Names: N-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide Molecular Formula: C24H25ClFN5O3 Molecular Weight: 485.94 Percent Composition: C 59.32%, H 5.19%, Cl 7.30%, F 3.91%, N 14.41%, O 9.88% Literature References: Irreversible pan-erbB tyrosine kinase inhibitor. Prepn: A. J. Bridges et al., WO 0031048; eidem, US 6344455 (2000, 2002 both to Warner-Lambert); J. B. Smaill et al., J. Med. Chem. 43, 1380 (2000). …
Cilastatin, циластатин , سيلاستاتين , 西司他丁 ,
It’s only fair to share… Cilastatin シラスタチン циластатин [Russian] [INN] سيلاستاتين [Arabic] [INN] 西司他丁 [Chinese] [INN] UNII141A6AMN38 CAS number 82009-34-5 WeightAverage: 358.453 Monoisotopic: 358.156242642 Chemical FormulaC16H26N2O5S (L)-7-(2-Amino-2-carboxy-ethylsulfanyl)-2-[(2,2-dimethyl-cyclopropanecarbonyl)-amino]-hept-2-enoic acid (Z)-(S)-6-carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteine (Z)-7-((R)-2-Amino-2-carboxy-ethylsulfanyl)-2-[((S)-2,2-dimethyl-cyclopropanecarbonyl)-amino]-hept-2-enoic acid (2Z)-7-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-2-{[(1S)-2,2-dimethylcyclopropyl]formamido}hept-2-enoic acid MK 0791|Primaxin® Primaxin® TL8005438 UNII:141A6AMN38 UNII-141A6AMN38 EINECS 279-875-8 Cilastatin CAS Registry Number: 82009-34-5 CAS Name: (2Z)-7-[[(2R)-2-Amino-2-carboxyethyl]thio]-2-[[[(1S)-2,2-dimethylcyclopropyl]carbonyl]amino]-2-heptenoic acid Manufacturers’ Codes: MK-791 Molecular Formula: C16H26N2O5S Molecular Weight: 358.45 Percent Composition: C 53.61%, H 7.31%, N 7.82%, …
J-147
It’s only fair to share… J-147 N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N’-[(E)-(3-methoxyphenyl)methylene]acetohydrazide Molecular FormulaC18H17F3N2O2 Average mass350.335 Da 2,2,2-trifluoroacetic acid-1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-[(1E)-(3-methoxyphenyl)methylene]hydrazide N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N’-[(E)-(3-methoxyphenyl)methylene]acetohydrazide [1146963-51-0] 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide, 2,2,2-trifluoro-acetic acid 1146963-51-0 [RN] DOUBLE BOND GEOMETRY UNSPECIFIED 1807913-16-1 [RN] AS PER https://chem.nlm.nih.gov/chemidplus/sid/1807913161 E FORM FDA UNII Z41H3C5BT9 Abrexa Pharmaceuticals, Dementia, Alzheimer’s type, PHASE1 Blanchette Rockefeller Neurosci Inst (Originator) Salk Institute for Biological Studies (Originator) Abrexa Pharmaceuticals is …
Dicycloplatin
It’s only fair to share… Dicycloplatin Platinum(2+) 1-carboxycyclobutanecarboxylate ammoniate (1:2:2) Molecular FormulaC12H20N2O8Pt Average mass515.380 Da 287402-09-9 Has antineoplastic activity; a supramolecular complex of 1,1-cyclobutane dicarboxylic acid and cis-diammine(1,1-cyclobutane dicarboxylate)platinum (II). 1,1-Cyclobutanedicarboxylic acid, ammonium platinum(2+) salt (2:2:1) [ACD/Index Name] Platinum(2+) 1-carboxycyclobutanecarboxylate ammoniate (1:2:2) 287402-09-9 [RN] DICYCLOPLATIN UNII:0KC57I4UNB Dicycloplatin is a chemotherapy medication used to treat a number of cancers …
Pretomanid, プレトマニド;
It’s only fair to share… Pretomanid プレトマニド; Formula C14H12F3N3O5 CAS 187235-37-6 Mol weight 359.2574 (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 187235-37-6 [RN] 2XOI31YC4N 5H-Imidazo(2,1-b)(1,3)oxazine, 6,7-dihydro-2-nitro-6-((4-(trifluoromethoxy)phenyl)methoxy)-, (6S)- 5H-Imidazo[2,1-b][1,3]oxazine, 6,7-dihydro-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-, (6S)- 9871 PA824 PA-824; Pretomanid (S)-PA 824 2019/8/14 FDA 2109 APPROVED Antibacterial (tuberculostatic), MP 149-150 °C, Li, Xiaojin; Bioorganic & Medicinal Chemistry Letters 2008, Vol 18(7), Pg 2256-2262 and Orita, Akihiro; Advanced Synthesis & Catalysis …
FDA approves first treatment Dupixent (Dupilumab) for chronic rhinosinusitis with nasal polyps
It’s only fair to share… The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity). This is the first treatment approved for inadequately controlled chronic rhinosinusis with nasal polyps. …
FDA approves first treatment Soliris (eculizumab) for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system
It’s only fair to share… The U.S. Food and Drug Administration today approved Soliris (eculizumab) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. NMOSD is an autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal …